The Immunological Landscape of M1 and M2 Macrophages and Their Spatial Distribution in Patients with Malignant Pleural Mesothelioma.
in silico analysis
malignant pleural mesothelioma
multiplex immunofluorescence
prognosis
transcriptoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Oct 2023
24 Oct 2023
Historique:
received:
07
09
2023
revised:
12
10
2023
accepted:
19
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Several tumor-associated macrophages (TAMs) have shown promise as prognosticators in cancer. Our aim was to validate the importance of TAMs in malignant pleural mesothelioma (MPM) using a two-stage design. We explored The Cancer Genome Atlas (TCGA-MESO) to select immune-relevant macrophage genes in MPM, including M1/M2 markers, as a discovery cohort. This computational cohort was used to create a multiplex immunofluorescence panel. Moreover, a cohort of 68 samples of MPM in paraffin blocks was used to validate the macrophage phenotypes and the co-localization and spatial distribution of these immune cells within the TME and the stromal or tumor compartments. The discovery cohort revealed six immune-relevant macrophage genes ( The interactions between TAMs in situ and, particularly, CD206
Sections du résumé
BACKGROUND
BACKGROUND
Several tumor-associated macrophages (TAMs) have shown promise as prognosticators in cancer. Our aim was to validate the importance of TAMs in malignant pleural mesothelioma (MPM) using a two-stage design.
METHODS
METHODS
We explored The Cancer Genome Atlas (TCGA-MESO) to select immune-relevant macrophage genes in MPM, including M1/M2 markers, as a discovery cohort. This computational cohort was used to create a multiplex immunofluorescence panel. Moreover, a cohort of 68 samples of MPM in paraffin blocks was used to validate the macrophage phenotypes and the co-localization and spatial distribution of these immune cells within the TME and the stromal or tumor compartments.
RESULTS
RESULTS
The discovery cohort revealed six immune-relevant macrophage genes (
CONCLUSIONS
CONCLUSIONS
The interactions between TAMs in situ and, particularly, CD206
Identifiants
pubmed: 37958292
pii: cancers15215116
doi: 10.3390/cancers15215116
pmc: PMC10650059
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Thorac Oncol. 2016 Oct;11(10):1765-73
pubmed: 27418105
Ann Transl Med. 2017 Jun;5(11):238
pubmed: 28706906
Ann Glob Health. 2016 Jan-Feb;82(1):209-13
pubmed: 27325079
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Cancers (Basel). 2022 Nov 16;14(22):
pubmed: 36428720
Respir Med. 2018 Jan;134:31-41
pubmed: 29413505
Genome Med. 2022 May 30;14(1):58
pubmed: 35637530
Lab Invest. 2017 Jan;97(1):4-13
pubmed: 27869795
J Exp Med. 2008 Jun 9;205(6):1261-8
pubmed: 18490490
J Thorac Oncol. 2013 Aug;8(8):e80-2
pubmed: 23857409
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Proc Natl Acad Sci U S A. 2023 Feb 28;120(9):e2210836120
pubmed: 36821580
J Invest Dermatol. 2014 Nov;134(11):2814-2822
pubmed: 24780929
Oncoimmunology. 2014 Jul 03;3(7):e946818
pubmed: 25610733
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25543-25552
pubmed: 32999071
Nucleic Acids Res. 2000 Sep 15;28(18):3442-4
pubmed: 10982861
Cell Immunol. 2018 Aug;330:188-201
pubmed: 29482836
PLoS One. 2015 Dec 23;10(12):e0145342
pubmed: 26699615
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
J Immunol. 2017 Oct 1;199(7):2191-2193
pubmed: 28923980
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33504575
Nucleic Acids Res. 2021 Oct 11;49(18):10800
pubmed: 34530444
Theranostics. 2018 Nov 12;8(21):5842-5854
pubmed: 30613266
ACS Nano. 2017 Sep 26;11(9):9536-9549
pubmed: 28858473
Cancers (Basel). 2020 Jan 21;12(2):
pubmed: 31972974
Transl Lung Cancer Res. 2018 Oct;7(5):574-583
pubmed: 30450296
Cell Death Discov. 2022 Nov 5;8(1):446
pubmed: 36335095
Lung Cancer. 2004 Aug;45 Suppl 1:S103-19
pubmed: 15261443
Int Immunopharmacol. 2014 Nov;23(1):37-45
pubmed: 25130606
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
JCI Insight. 2022 Jun 8;7(11):
pubmed: 35503656
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Nat Commun. 2019 Sep 2;10(1):3928
pubmed: 31477692
Oncoimmunology. 2015 May 26;4(11):e1047584
pubmed: 26451326
J Invest Dermatol. 2015 Oct;135(10):2547-2550
pubmed: 26016897
J Invest Dermatol. 2011 Jun;131(6):1322-30
pubmed: 21307877
Nat Rev Immunol. 2014 Feb;14(2):81-93
pubmed: 24445666
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-10402
pubmed: 16798876
Sci Rep. 2021 Apr 19;11(1):8511
pubmed: 33875760
Ther Clin Risk Manag. 2008 Feb;4(1):205-11
pubmed: 18728709
PLoS One. 2012;7(12):e50946
pubmed: 23284651
PLoS One. 2017 Apr 12;12(4):e0174968
pubmed: 28403150
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
J Clin Invest. 1996 Nov 1;98(9):2050-9
pubmed: 8903324
Immunobiology. 2018 Apr - May;223(4-5):383-396
pubmed: 29146235
Immunobiology. 2017 Jul;222(7):847-856
pubmed: 28318799
Front Oncol. 2018 Jan 23;8:3
pubmed: 29410946
Scand J Immunol. 2022 Apr;95(4):e13137
pubmed: 34964155
Int J Cancer. 2013 Dec 15;133(12):2884-94
pubmed: 23740735
Front Mol Biosci. 2021 Jun 14;8:668340
pubmed: 34179080
Am J Transl Res. 2012;4(4):376-89
pubmed: 23145206
Trends Immunol. 2019 Apr;40(4):310-327
pubmed: 30890304
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32780802
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
J Thorac Oncol. 2016 Oct;11(10):1755-64
pubmed: 27418106
Nature. 2013 Apr 25;496(7446):445-55
pubmed: 23619691
Nat Commun. 2021 Feb 9;12(1):877
pubmed: 33563975
Neoplasia. 2022 Mar;25:18-27
pubmed: 35078134
JAKSTAT. 2013 Jan 1;2(1):e23820
pubmed: 24058799
Precis Cancer Med. 2021 Sep;4:
pubmed: 35098108
Dis Model Mech. 2008 Sep-Oct;1(2-3):155-67; discussion 165
pubmed: 19048079
J Invest Dermatol. 2015 Nov;135(11):2884-2887
pubmed: 26053051
Ann Glob Health. 2016 Jan-Feb;82(1):214-6
pubmed: 27325080
Dis Markers. 2017;2017:1310478
pubmed: 29085180
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S39-S46
pubmed: 32206569
Front Immunol. 2014 Mar 26;5:127
pubmed: 24723924